COVID-19 Variants of Concern: Difference between revisions
Jump to navigation
Jump to search
Mohamed riad (talk | contribs) |
Mohamed riad (talk | contribs) |
||
| Line 26: | Line 26: | ||
|NR-54000external icon | |NR-54000external icon | ||
| | | | ||
* Approximately 50% increased transmissibility | *Approximately 50% increased transmissibility | ||
* Increased severity according to hospitalizations and case fatality rates | *Increased severity according to hospitalizations and case fatality rates | ||
* Little effect on neutralization by convalescent and post-vaccination sera | *Little effect on neutralization by convalescent and post-vaccination sera | ||
|- | |- | ||
|Beta B.1.357 | |Beta B.1.357 | ||
| Line 36: | Line 36: | ||
|NR-55282 | |NR-55282 | ||
| | | | ||
* Approximately 50% increased transmissibility | *Approximately 50% increased transmissibility | ||
* A marked decrease in the susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment; however, other EUA monoclonal antibody treatments are available | *A marked decrease in the susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment; however, other EUA monoclonal antibody treatments are available | ||
* Decreased neutralization by convalescent and post-vaccination sera | *Decreased neutralization by convalescent and post-vaccination sera | ||
|- | |- | ||
|Gamma P.1 | |Gamma P.1 | ||
| Line 46: | Line 46: | ||
|NR-54982 | |NR-54982 | ||
| | | | ||
* A marked decrease in the susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment; however, other EUA monoclonal antibody treatments are available | *A marked decrease in the susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment; however, other EUA monoclonal antibody treatments are available | ||
* Decreased neutralization by convalescent and post-vaccination sera | *Decreased neutralization by convalescent and post-vaccination sera | ||
|- | |- | ||
|Delta B.1.617.2 | |Delta B.1.617.2 | ||
|21A/S:478K | |||
|India | |||
|T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R, D950N | |||
| | | | ||
| | | | ||
* Increased transmissibility | |||
* Decreased neutralization by some EUA monoclonal antibody treatments | |||
* Significant decrease in neutralization by post-vaccination sera | |||
|- | |- | ||
|Lambda C.37 | |Lambda C.37 | ||
| | | | ||
| | |Peru | ||
| | |L452Q, F490S, D614G | ||
| | | | ||
| | | | ||
Revision as of 04:46, 20 August 2021
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 Variants of Concern On the Web |
|
American Roentgen Ray Society Images of COVID-19 Variants of Concern |
|
Risk calculators and risk factors for COVID-19 Variants of Concern |
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:
Overview
Variants of Concern
Alpha B.1.1.7
| Name | First Discovered | Spike Protein Substitutions | BEI Reference Isolate | Importance | |
|---|---|---|---|---|---|
| Alpha B.1.1.7 | 20I/501Y.V1 | United Kingdom | 69del, 70del, 144del, (E484K*), (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*) | NR-54000external icon |
|
| Beta B.1.357 | 20H/501.V2 | South Africa | D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701V | NR-55282 |
|
| Gamma P.1 | 20J/501Y.V3 | Brazil and Japan | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I | NR-54982 |
|
| Delta B.1.617.2 | 21A/S:478K | India | T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R, D950N |
| |
| Lambda C.37 | Peru | L452Q, F490S, D614G |